Perturbing mitosis for anti-cancer therapy: is cell death the only answer?

EMBO Rep. 2018 Mar;19(3):e45440. doi: 10.15252/embr.201745440. Epub 2018 Feb 19.

Abstract

Interfering with mitosis for cancer treatment is an old concept that has proven highly successful in the clinics. Microtubule poisons are used to treat patients with different types of blood or solid cancer since more than 20 years, but how these drugs achieve clinical response is still unclear. Arresting cells in mitosis can promote their demise, at least in a petri dish. Yet, at the molecular level, this type of cell death is poorly defined and cancer cells often find ways to escape. The signaling pathways activated can lead to mitotic slippage, cell death, or senescence. Therefore, any attempt to unravel the mechanistic action of microtubule poisons will have to investigate aspects of cell cycle control, cell death initiation in mitosis and after slippage, at single-cell resolution. Here, we discuss possible mechanisms and signaling pathways controlling cell death in mitosis or after escape from mitotic arrest, as well as secondary consequences of mitotic errors, particularly sterile inflammation, and finally address the question how clinical efficacy of anti-mitotic drugs may come about and could be improved.

Keywords: BCL2 family; apoptosis; mitotic arrest; p53; slippage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis / genetics
  • Cell Cycle Checkpoints / genetics
  • Cell Death / genetics*
  • Humans
  • Microtubules / genetics
  • Mitosis / genetics*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Neoplasms / therapy*